Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17582177 | 0.87 | SCN9A (0.35) | KDM1AKDM1BRIPK1SCN9ANTRK1 | |
| SCHEMBL17582007 | 0.87 | SCN9A (0.35) | KDM1AKDM1BRIPK1SCN9ANTRK1 | |
| SCHEMBL17848842 | 0.75 | KDM1A (0.41) | KDM1AKDM1BRIPK1SCN9ANTRK1 | |
| SCHEMBL17848844 | 0.75 | KDM1A (0.41) | KDM1AKDM1BRIPK1SCN9ANTRK1 | |
| SCHEMBL24200528 | 0.73 | KDM1A (0.45) | KDM1AKDM1BRIPK1SCN9ADPP4 | |
| SCHEMBL17820748 | 0.72 | NTRK1 (0.44) | RIPK1SCN9ANTRK1 | |
| SCHEMBL17820744 | 0.72 | NTRK1 (0.44) | RIPK1SCN9ANTRK1 | |
| SCHEMBL17821025 | 0.72 | NTRK1 (0.44) | RIPK1SCN9ANTRK1 | |
| SCHEMBL23083856 | 0.72 | NTRK1 (0.44) | RIPK1SCN9ANTRK1 | |
| SCHEMBL16310710 | 0.70 | KDM1A (0.45) | KDM1AKDM1BRIPK1SCN9ANTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783527-B2 | Indazole ureas and method of use | ABBVIE INC. (US) | 2017-10-10 | — | — | US | disclosed |
| EP-3194404-A1 | INDAZOLE UREAS AND METHOD OF USE | AbbVie Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044386-A1 | INDAZOLE UREAS AND METHOD OF USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075692-A1 | Indazole Ureas and Method of Use | ABBVIE INC. (US) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075692-A1 | Indazole Ureas and Method of Use | SCN8A, SCN7A, SCN3A | KDM1A 1773/4885KDM1B 1861/4885RIPK1 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.